• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Beta Bionics Inc.

    2/24/26 5:00:31 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care
    Get the next $BBNX alert in real time by email
    S-8 1 d795774ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 24, 2026

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Beta Bionics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   47-5386878

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    11 Hughes

    Irvine, California 92618

      92618
    (Address of Principal Executive Offices)   (Zip Code)

    Beta Bionics, Inc. 2025 Equity Incentive Plan

    Beta Bionics, Inc. 2025 Employee Stock Purchase Plan

    (Full titles of the plans)

    Sean Saint

    President and Chief Executive Officer

    Beta Bionics, Inc.

    11 Hughes

    Irvine, California 92618

    (949) 427-7785

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Carlos Ramirez

    Mark Weeks

    Cooley LLP

    10265 Science Center Drive

    San Diego, CA 92121

    (858) 550-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Beta Bionics, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plans is effective. The Registrant previously registered its shares of common stock, par value $0.0001 per share, for issuance under the Registrant’s 2025 Equity Incentive Plan and the Registrant’s 2025 Employee Stock Purchase Plan under the Registrant’s Registration Statement on Form S-8 (the “Prior Registration Statement”) filed with the Commission on February 3, 2025 (File No. 333-284655). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statement referenced above.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

     

      (a)

    The Registrant’s Current Report on Form 8-K filed with the Commission on January 30, 2026 (File No. 001-42491) (to the extent the information in such report is filed and not furnished);

     

      (b)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 24, 2026 (File No. 001-42491); and

     

      (c)

    The description of the Registrant’s common stock contained in the Registrant’s Registration Statement on Form 8-A filed on January 27, 2025 (File No. 001-42491) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2024, filed with the Commission on March 28, 2025 (File No. 001-42491).

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.


    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed below:

     

    Exhibit
    Number
      

    Description of Exhibit

       Form      File No.      Exhibit      Filing
    Date
         Filed
    Herewith
     
      4.1    Amended and Restated Certificate of Incorporation of the Registrant.      8-K        001-42491        3.1        01/31/25     
      4.2    Amended and Restated Bylaws of the Registrant.      S-1        333-284147        3.4        01/06/25     
      4.3    Form of Common Stock Certificate.      S-1/A        333-284147        4.1        01/22/25     
      4.4    Amended and Restated Investor Rights Agreement, dated November 8, 2024, by and among the Registrant and certain of its stockholders.      S-1        333-284147        4.2        01/06/25     
      5.1    Opinion of Cooley LLP.                  X  
     23.1    Consent of Independent Registered Public Accounting Firm.                  X  
     23.2    Consent of Cooley LLP (included in Exhibit 5.1).                  X  
     24.1    Power of Attorney (included on signature page).                  X  
     99.1    Beta Bionics, Inc. 2025 Equity Incentive Plan.      S-8        333-284655        99.3        02/03/25     
     99.2    Beta Bionics, Inc. 2025 Employee Stock Purchase Plan.      S-8        333-284655        99.8        02/03/25     
    107    Filing Fee Table.                  X  


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, California, on February 24, 2026.

     

    BETA BIONICS, INC.

    By:   /s/ Sean Saint
      Sean Saint
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean Saint and Stephen Feider and each of them, as his or her true and lawful attorneys-in-fact and agents, and each of them, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Sean Saint

    Sean Saint

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      February 24, 2026

    /s/ Stephen Feider

    Stephen Feider

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      February 24, 2026

    /s/ Adam Lezack

    Adam Lezack

       Chairperson of the Board of Directors   February 24, 2026

    /s/ Sean Carney

    Sean Carney

       Director   February 24, 2026

    /s/ Dan Dearen

    Dan Dearen

       Director   February 24, 2026

    /s/ Christy Jones

    Christy Jones

       Director   February 24, 2026

    /s/ Gerard Michel

    Gerard Michel

       Director   February 24, 2026

    /s/ Maria Palasis, Ph.D.

    Maria Palasis, Ph.D.

       Director   February 24, 2026
    Get the next $BBNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBNX

    DatePrice TargetRatingAnalyst
    2/9/2026$24.00Buy
    UBS
    1/27/2026$17.00Hold
    TD Cowen
    1/9/2026Buy → Neutral
    BofA Securities
    10/21/2025$26.00Buy
    Stifel
    10/1/2025$26.00Neutral → Buy
    Goldman
    6/16/2025$26.00Buy
    Truist
    6/12/2025$30.00Buy
    Lake Street
    5/30/2025$16.00Neutral
    Goldman
    More analyst ratings

    $BBNX
    SEC Filings

    View All

    SEC Form S-3ASR filed by Beta Bionics Inc.

    S-3ASR - Beta Bionics, Inc. (0001674632) (Filer)

    2/24/26 5:03:29 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Beta Bionics Inc.

    S-8 - Beta Bionics, Inc. (0001674632) (Filer)

    2/24/26 5:00:31 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Beta Bionics Inc.

    10-K - Beta Bionics, Inc. (0001674632) (Filer)

    2/24/26 4:20:52 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Beta Bionics with a new price target

    UBS initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $24.00

    2/9/26 7:00:55 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Beta Bionics with a new price target

    TD Cowen initiated coverage of Beta Bionics with a rating of Hold and set a new price target of $17.00

    1/27/26 8:43:35 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics downgraded by BofA Securities

    BofA Securities downgraded Beta Bionics from Buy to Neutral

    1/9/26 8:48:15 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Mensinger Mike bought $566,950 worth of shares (33,350 units at $17.00), converted options into 15,107 shares, exercised 10,575 in-the-money shares at a strike of $0.02 and sold $221 worth of shares (13 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 8:30:15 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 4:49:52 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Michel Gerard J was granted 3,997 shares, increasing direct ownership by 32% to 16,544 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    1/14/26 8:30:13 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Director Palasis Maria was granted 3,997 shares, increasing direct ownership by 47% to 12,432 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    1/14/26 8:30:10 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Director Carney Sean was granted 3,997 shares, increasing direct ownership by 36% to 15,244 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    1/14/26 8:30:11 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference

    IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen's 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time). A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay following the event. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, a

    2/19/26 4:05:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026

    IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2025 and introduced its annual guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial Highlights & Key Metrics Net sales of $32.1 million, up 57% compared to $20.4 million in the fourth quarter of 2024. Durable Medical Equipment (DME) channel net sales of $22.3 million, up 24% compared to $18.0 million in the fourth quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $9.8 million, up 295% compared to $2.5 mill

    2/17/26 4:05:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2025 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archi

    1/15/26 4:03:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    Beta Bionics Announces Board Appointment of Gerard Michel

    IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

    3/27/25 4:45:06 PM ET
    $BBNX
    $DCTH
    Medical/Dental Instruments
    Health Care

    $BBNX
    Financials

    Live finance-specific insights

    View All

    Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026

    IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2025 and introduced its annual guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial Highlights & Key Metrics Net sales of $32.1 million, up 57% compared to $20.4 million in the fourth quarter of 2024. Durable Medical Equipment (DME) channel net sales of $22.3 million, up 24% compared to $18.0 million in the fourth quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $9.8 million, up 295% compared to $2.5 mill

    2/17/26 4:05:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2025 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archi

    1/15/26 4:03:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

    IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025. Members of the Company's management team will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 financial results and key metrics set forth below. The Company invites investors to register for in-person meetings by contacting the Company's investor relations representative at [email protected]. Preliminary, Un

    1/8/26 4:04:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care